Advocating for creative communities and entrepreneurs since 2003
Headquartered in New York City with a satellite office in Los Angeles, Harris Ingram LLP represents creative clients on and between coasts. Our firm specializes in all Intellectual Property matters, from the seed of an idea to the final product. Whether you’re a musician, designer, engineer, or small business owner, we will not only protect what you create, but we’ll also help it thrive in the world. We bring extensive experience and professionalism to every case and customize our support to your individual needs and concerns.
Our attorneys have been practicing for over a decade and started during the .com internet boom of the late 90s. We’re on the pulse of modern technology and media, and have monitored their evolution to inform our own legal approaches—all to give you exceptional advice that will last for years to come.
Get in touch with us to set up a consultation, or use the contact form at the bottom of this page to enquire whether our services are right for you.
Contact
➤ LOCATION
777 Nameless Ave.
New York, NY 00000
☎ CONTACT
placeholder@example.com
(212) 555-0110
Areas of Practice
Models and methods
“Workhorse” methods/models such as survival analysis (Cox model for the event hazard, Kaplan-Meir and Nelson-Aalen estimators of the survival function; Restricted Mean Survival Time); Longitudinal analysis (Linear Mixed models, LMMs; Generalized Linear Mixed Models, GLMMs)
Fixed designs
Continuous Reassessment Method (CRM) for dose-response (efficacy and toxicity); crossover designs, …
simulation methods
Generating quality data to test your designs and models is essential: event times (correlated endpoints such as PFS and OS; recurrent events), longitudinal data …..
Adaptive designs
Confused between the array of different design options and their relative pros and cons?
Training
The internet, software, and technology are so pervasive that we can’t remember having ever lived without them. They make our lives simpler, but behind the curtain are fluctuating challenges in protection and monetization—challenges that our firm stays two steps ahead of.
due-DILIGENCE
With a plethora of exciting new treatment modalities emerging across a range of disease areas (i.e. mRNA vaccines for respiratory viruses, immunotherapies and ADCs for various cancers) the number of opportunities for investments in early stage biotech companies is large, however the risks of failure of a nascent drug candidate are high. Making sense of the early data about the asset and how this fits into the competitive landscape is crucial to making sound investment decisions.
Whether the data consists of large numbers of analyses from pre-clinical genomics or translational data where multiple testing issues or small data might be a risk, or whether the data comes from phase 1 and/or 2 clinical data where an overly ambitious clinical development plan (CDP) for phase 3 has been developed, we can help identify these risks, provide contextualisation and alternative viewpoints, or reverse-engineer CDPs to expose opaque assumptions.
“Whatever the progress of human knowledge, there will always be room for ignorance, hence for chance and probability.”
Let's Chat.
Use the form below to contact us regarding your legal enquiry. Please be as detailed as possible. Include your industry along with any specific document requests. To help us best service your enquiry, we recommend that you first describe the issue you’re having before telling us what you want to achieve. You may also email or call us to make an appointment.
For job opportunities, please email us your resume. We’re always looking for new and exceptional talent to lead the firm into uncharted fields of practice.